Envigo offers the Wistar Institute Melanoma (WM) PDX model collection established from targeted therapy relapsed melanoma patients, spanning BRAF inhibitors, BRAK/MEK inhibitors, immune checkpoint inhibitors and targeted therapy and immunotherapy (TT/IT) combinations.

    • Vials of cells available
    • In vivo propagation
    • Efficacy studies


    Read about testing second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models in Clinical Cancer Research by Krepler et al.

    Further reading:

    Xiao et al. (2019). A Melanoma Patient-Derived Xenograft Model. Journal of visualized experiments : JoVE, (147), 10.3791/59508.

    Order today

    +1 800 793 7287

    Online order